Our lead product, the Ceramide NanoLiposome (CNL), is approximately 80 nanometers in size, has robust stability both in storage and in blood and is suitable for large-scale manufacturing. Through in vivo models, the CNL has demonstrated the ability to treat a wide range of poorly treated cancers, including liver cancer, certain leukemias, pancreatic cancer and breast cancer.
The National Cancer Institutes Nanocharacterization Laboratory has studied Ceramide NanoLiposomes extensively and published a report on key characteristics, including preclinical toxicity screening.
Keystone Nano has scaled several liposomal formulations from small scale extrusion syntheses to a homogenization/extrusion manufacturing system capable of producing preclinical and clinical testing materials. In collaboration with regulatory consultants and advisors we have also designed preclinical testing programs to support investigational new drug (IND) applications to the FDA.
Key benefits of NanoLiposome technology include:
- Composition: NanoLiposomes are made up of lipids, most of which occur naturally within the body.
- Size and stability: Typically 60-80 nanometers, our liposomes are stable in blood, circulate well, and easily enter tumor cells to deliver their payloads, destroying cancer cells.
- Active ingredients: We can load both water-loving (hydrophilic) and water-hating (hydrophobic) compounds into NanoLiposomes.
- Protection: Actives are stored either within the liposomal core or lipid bilayer, preventing degradation during circulation.
- Delivery: NanoLiposomes are stable during circulation and release payloads intracellularly following membrane fusion.
- Targeting: NanoLiposomes can be targeted through size and surface charge, or a wide range of targeting materials can be attached to the surface.